Pfizer (PFE) Tops Q1 EPS by 29c, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Pfizer stock climbs as first quarter earnings, revenue come ahead of estimates
May 1, 2024 6:53 AM EDTPfizer (NYSE: PFE) shares rose 3% in premarket trading Wednesday after the drugmaker reported Q1 earnings and revenue that beat analyst estimates.
Earnings per share (EPS) stood at $0.82, exceeding the consensus estimates of $0.53. Revenue came in at $14.9 billion, also above the consensus projection of $14.04 billion.
Meanwhile, adjusted research and development (R&D) expenses... More
